Protective Effects of Activated Myofibroblasts in the Pressure-Overloaded Myocardium Are Mediated Through Smad-Dependent Activation of a Matrix-Preserving Program.
Animals
Cell Adhesion Molecules
/ metabolism
Extracellular Matrix Proteins
/ metabolism
Matrix Metalloproteinase 8
/ metabolism
Matrix Metalloproteinase Inhibitors
/ pharmacology
Mice
Mice, Knockout
Myofibroblasts
/ metabolism
Pressure
Smad3 Protein
/ genetics
Stress, Mechanical
Stroke Volume
Tissue Inhibitor of Metalloproteinase-1
/ metabolism
Transforming Growth Factor beta1
/ metabolism
Transforming Growth Factor beta2
/ metabolism
Transforming Growth Factor beta3
/ metabolism
Ventricular Remodeling
extracellular matrix
fibroblasts
inflammation
macrophages
matrix metalloproteinases
Journal
Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103
Informations de publication
Date de publication:
12 04 2019
12 04 2019
Historique:
pubmed:
29
1
2019
medline:
24
1
2020
entrez:
29
1
2019
Statut:
ppublish
Résumé
The heart contains abundant interstitial and perivascular fibroblasts. Traditional views suggest that, under conditions of mechanical stress, cytokines, growth factors, and neurohumoral mediators stimulate fibroblast activation, inducing ECM (extracellular matrix) protein synthesis and promoting fibrosis and diastolic dysfunction. Members of the TGF (transforming growth factor)-β family are upregulated and activated in the remodeling myocardium and modulate phenotype and function of all myocardial cell types through activation of intracellular effector molecules, the Smads (small mothers against decapentaplegic), and through Smad-independent pathways. To examine the role of fibroblast-specific TGF-β/Smad3 signaling in the remodeling pressure-overloaded myocardium. We examined the effects of cell-specific Smad3 loss in activated periostin-expressing myofibroblasts using a mouse model of cardiac pressure overload, induced through transverse aortic constriction. Surprisingly, FS3KO (myofibroblast-specific Smad3 knockout) mice exhibited accelerated systolic dysfunction after pressure overload, evidenced by an early 40% reduction in ejection fraction after 7 days of transverse aortic constriction. Accelerated systolic dysfunction in pressure-overloaded FS3KO mice was associated with accentuated matrix degradation and generation of collagen-derived matrikines, accompanied by cardiomyocyte myofibrillar loss and apoptosis, and by enhanced macrophage-driven inflammation. In vitro, TGF-β1, TGF-β2, and TGF-β3 stimulated a Smad3-dependent matrix-preserving phenotype in cardiac fibroblasts, suppressing MMP (matrix metalloproteinase)-3 and MMP-8 synthesis and inducing TIMP (tissue inhibitor of metalloproteinases)-1. In vivo, administration of an MMP-8 inhibitor attenuated early systolic dysfunction in pressure-overloaded FS3KO mice, suggesting that the protective effects of activated cardiac myofibroblasts in the pressure-overloaded myocardium are, at least in part, because of suppression of MMPs and activation of a matrix-preserving program. MMP-8 stimulation induces a proinflammatory phenotype in isolated macrophages. In the pressure-overloaded myocardium, TGF-β/Smad3-activated cardiac fibroblasts play an important protective role, preserving the ECM network, suppressing macrophage-driven inflammation, and attenuating cardiomyocyte injury. The protective actions of the myofibroblasts are mediated, at least in part, through Smad-dependent suppression of matrix-degrading proteases.
Identifiants
pubmed: 30686120
doi: 10.1161/CIRCRESAHA.118.314438
pmc: PMC6459716
mid: NIHMS1519856
doi:
Substances chimiques
Cell Adhesion Molecules
0
Extracellular Matrix Proteins
0
Matrix Metalloproteinase Inhibitors
0
POSTN protein, human
0
Smad3 Protein
0
Smad3 protein, mouse
0
TIMP1 protein, human
0
Tissue Inhibitor of Metalloproteinase-1
0
Transforming Growth Factor beta1
0
Transforming Growth Factor beta2
0
Transforming Growth Factor beta3
0
Matrix Metalloproteinase 8
EC 3.4.24.34
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1214-1227Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL076246
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL085440
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL135657
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR027701
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Semin Immunopathol. 2015 Sep;37(5):559-63
pubmed: 26141607
JAMA Cardiol. 2017 Sep 1;2(9):995-1006
pubmed: 28768311
JACC Cardiovasc Imaging. 2016 Sep;9(9):1046-1055
pubmed: 27450871
Circ Res. 2017 Aug 18;121(5):575-583
pubmed: 28630135
J Clin Invest. 2014 May;124(5):2136-46
pubmed: 24743145
J Clin Invest. 2017 Jan 3;127(1):383-401
pubmed: 27918308
Circ Heart Fail. 2009 Nov;2(6):633-42
pubmed: 19919989
Am J Pathol. 2008 Jul;173(1):144-53
pubmed: 18556780
FASEB J. 2007 Aug;21(10):2580-91
pubmed: 17392479
J Clin Invest. 2017 Oct 2;127(10):3675-3688
pubmed: 28872461
J Clin Invest. 2014 Jul;124(7):2921-34
pubmed: 24937432
Int J Exp Pathol. 2004 Apr;85(2):47-64
pubmed: 15154911
Gut. 2014 Apr;63(4):578-87
pubmed: 23525573
Cell. 2003 Jun 13;113(6):685-700
pubmed: 12809600
Hypertension. 2010 May;55(5):1165-71
pubmed: 20231525
Circ Res. 2014 Sep 12;115(7):625-35
pubmed: 25037571
Circulation. 2011 Nov 8;124(19):2094-105
pubmed: 21986284
Basic Res Cardiol. 2017 Mar;112(2):19
pubmed: 28238121
Circ Heart Fail. 2015 Jul;8(4):788-98
pubmed: 25985794
Circulation. 2018 Feb 13;137(7):707-724
pubmed: 29229611
Circulation. 2007 Nov 6;116(19):2127-38
pubmed: 17967775
PLoS One. 2007 Mar 21;2(3):e312
pubmed: 17375198
Nat Rev Cardiol. 2017 Aug;14(8):484-491
pubmed: 28436487
J Mol Cell Cardiol. 2014 May;70:74-82
pubmed: 24321195
Am J Pathol. 1995 Aug;147(2):325-38
pubmed: 7639329
Nat Commun. 2017 Mar 22;8:14913
pubmed: 28327610
J Exp Med. 2017 Nov 6;214(11):3293-3310
pubmed: 28978634
Nat Commun. 2016 Jul 22;7:12260
pubmed: 27447449
Front Biosci. 2007 Jan 01;12:507-27
pubmed: 17127313
J Immunol. 2008 Apr 15;180(8):5662-9
pubmed: 18390751
J Immunol. 2014 Sep 1;193(5):2384-93
pubmed: 25049354
Circ Res. 2006 Apr 28;98(8):1032-9
pubmed: 16556868
J Clin Invest. 2010 Jan;120(1):254-65
pubmed: 20038803
J Clin Invest. 2017 Oct 2;127(10):3770-3783
pubmed: 28891814
Circ Res. 2009 Dec 4;105(12):1164-76
pubmed: 19959782
Am J Respir Crit Care Med. 2014 Oct 15;190(8):867-78
pubmed: 25090037
Growth Factors. 2011 Oct;29(5):196-202
pubmed: 21740331
J Immunol. 2013 Nov 1;191(9):4838-48
pubmed: 24078695
Circ Res. 2016 Feb 5;118(3):400-9
pubmed: 26635390
J Immunol. 2004 Aug 1;173(3):2099-108
pubmed: 15265946
Histochem Cell Biol. 2009 Apr;131(4):471-81
pubmed: 19030868
Circ Res. 2010 Aug 6;107(3):418-28
pubmed: 20522804
Circ Res. 2007 Aug 3;101(3):313-21
pubmed: 17569887
Circ Res. 2016 Oct 28;119(10):1049-1051
pubmed: 27789580
J Mol Cell Cardiol. 2014 Mar;68:56-65
pubmed: 24440456
Mol Cell Biol. 2008 Dec;28(23):7001-11
pubmed: 18809571
PLoS One. 2012;7(6):e39940
pubmed: 22768176